Pfenex Inc. Welcomes Kristi Sarno as a Director of Business Development

San Diego, CA, December 5, 2012 Pfenex Inc. today announced that Kristi Sarno has joined the company as a Director of Business Development.

In her role at Pfenex, Kristi will be primarily responsible for prospecting Pfenex Expression Technology™ strain engineering and licensing opportunities with small to mid size biotechnology companies, developing business with several large pharmaceutical accounts and also prospecting government opportunities. Kristi will be based in the greater Boston area. “We are thrilled to have Kristi join the Pfenex team,” stated Patrick Lucy, Vice President of Business Development and Marketing, “Kristi brings sixteen years of experience within the pharmaceutical and biotechnology markets, and will be a key contributor to our business development efforts.”

Most recently, Kristi held the position of Director of Business Development at Laureate Biopharma. In her role at Laureate, Kristi was responsible for securing contract manufacturing contracts from a broad range of industry clients. Prior to Laureate Kristi was the Associate Director, Business Development for Crucell Holland, based at Percivia. In this role, Kristi managed the Strategic Alliance Group for Per.C6 partnerships, providing both technical and contractual support for licensees. Kristi’s early career was spent in research positions with venerable institutions such as Boston Children’s Hospital, Beth Israel Deaconess, and American Red Cross. Kristi earned her ALM (Master of Liberal Arts) in Biology at Harvard University and her BS in Biology at Syracuse University.

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars, and innovator biopharmaceuticals. For more information, visit

Pfenex Inc. Contact

Cassidy Brady

Sr. Marketing Manager

Pfenex Inc.


Back to news